Afshin Dowlati, MD
- Disease Team Leader - Lung Cancer and Thoracic Scientific Team, UH Cleveland Medical Center
- Lucile and Robert H Gries Endowed Director, Center for Cancer Drug Development, University Hospitals
- Professor, CWRU School of Medicine
- Director, Thoracic Oncology Program, UH Seidman Cancer Center
- Experimental Therapeutics
- Lung Cancer
- Phase I Clinical Trials
- Thoracic Cancer
English, French, Farsi
Patient Satisfaction Reviews
4.9 out of 5
Patient Comments (15)
Reviewed On 5/1/2020
I am in chemotharaphy and see the Dr. every 3 weeks. He is wonderful. He always takes the time to talk to me and discuss what the future plans are.
Reviewed On 3/5/2020
Dr Dowlati is laser-focused!
Reviewed On 2/26/2020
the dr & team are always great [...]
Reviewed On 2/25/2020
We had an excellent visit and future plans were discussed. He also reviews my scans and records himself, which impresses me that he takes the time to do that. Also, very impresive, is that he talks to my husband and me and is NOT typing on a computer as so many Doctors do now. We feel fortunate that we have Dr. Dowlati as our Oncologist.
Reviewed On 2/3/2020
care transferred to new oncologist with expertise in my type of cancer. Doctor has been extremely kind to me while I was under his care.
Reviewed On 2/1/2020
Dr Dowlati always takes the time to review my complicated medical history and reviews my current treatment plan. If I ever decide to move out of the area I will travel here to see this physician, he is that good!
Reviewed On 1/10/2020
Appreciated the sincere interest he showed to me during my visit. Was thorough and not rushed, and spent extra time answering our questions. Obviously he was seeking all the information I could provide to ensure my treatment plan was appropriate for me.
Reviewed On 11/11/2019
very smooth and never rushed.
Reviewed On 10/27/2019
Excellent, professional and very comforting.
Reviewed On 10/10/2019
can't say enough good about the care I received. Dr. Dowloti and his staff are second to none.
Reviewed On 9/22/2019
Reviewed On 9/4/2019
best dr and staff I've ever had!. [...]
Reviewed On 8/28/2019
Spent a lot of time with my dad. Very caring and explained things well
Reviewed On 8/20/2019
Reviewed On 8/19/2019
always treated well.
- Medical Oncology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Residency | Internal Medicine
Internal Medicine - University Hospitals Of Cleveland (1998 - 2000)
Fellowship | Hematology/Oncology
Hematology/Oncology - University Hospitals Of Cleveland (1996 - 1998)
Internship | Internal Medicine
Internal Medicine - Universite De Liege Faculte De Medecine (1992 - 1996)
Universite De Liege Faculte De Medecine (1992)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Afshin Dowlati did not disclose any Outside Relationships with Industry.